120 related articles for article (PubMed ID: 18251152)
1. Budesonide in Crohn's disease: findings of a compassionate-use program.
Lyckegaard E; Håkansson K; Bengtsson B
Hepatogastroenterology; 2007; 54(79):2024-7. PubMed ID: 18251152
[TBL] [Abstract][Full Text] [Related]
2. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group.
Greenberg GR; Feagan BG; Martin F; Sutherland LR; Thomson AB; Williams CN; Nilsson LG; Persson T
N Engl J Med; 1994 Sep; 331(13):836-41. PubMed ID: 8078529
[TBL] [Abstract][Full Text] [Related]
3. A comparison of budesonide with prednisolone for active Crohn's disease.
Rutgeerts P; Löfberg R; Malchow H; Lamers C; Olaison G; Jewell D; Danielsson A; Goebell H; Thomsen OO; Lorenz-Meyer H
N Engl J Med; 1994 Sep; 331(13):842-5. PubMed ID: 8078530
[TBL] [Abstract][Full Text] [Related]
4. Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysis.
Lichtenstein GR; Bengtsson B; Hapten-White L; Rutgeerts P
Aliment Pharmacol Ther; 2009 Mar; 29(6):643-53. PubMed ID: 19035972
[TBL] [Abstract][Full Text] [Related]
5. Treatment of active and postactive ileal and colonic Crohn's disease with oral pH-modified-release budesonide. German Budesonide Study Group.
Caesar I; Gross V; Roth M; Andus T; Schmidt C; Raedsch R; Weber A; Gierend M; Ewe K; Schölmerich J
Hepatogastroenterology; 1997; 44(14):445-51. PubMed ID: 9164517
[TBL] [Abstract][Full Text] [Related]
6. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial.
Hanauer S; Sandborn WJ; Persson A; Persson T
Aliment Pharmacol Ther; 2005 Feb; 21(4):363-71. PubMed ID: 15709986
[TBL] [Abstract][Full Text] [Related]
7. Beclomethasone dipropionate for the treatment of mild-to-moderate Crohn's disease: an open-label, budesonide-controlled, randomized study.
Tursi A; Giorgetti GM; Brandimarte G; Elisei W; Aiello F
Med Sci Monit; 2006 Jun; 12(6):PI29-32. PubMed ID: 16733496
[TBL] [Abstract][Full Text] [Related]
8. Budesonide modified-release capsules.
Baker DE
Rev Gastroenterol Disord; 2001; 1(3):147-55. PubMed ID: 12120182
[TBL] [Abstract][Full Text] [Related]
9. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission.
Sandborn WJ; Feagan BG; Lichtenstein GR
Aliment Pharmacol Ther; 2007 Oct; 26(7):987-1003. PubMed ID: 17877506
[TBL] [Abstract][Full Text] [Related]
10. Budesonide for Crohn's disease.
Seow CH; Benchimol EI; Steinhart AH; Griffiths AM; Otley AR
Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):971-9. PubMed ID: 19611401
[TBL] [Abstract][Full Text] [Related]
11. Maintenance treatment with budesonide 6 mg versus 9 mg once daily in patients with Crohn's disease in remission.
de Jong DJ; Bac DJ; Tan G; de Boer SY; Grabowsky IL; Jansen JB; Greinwald R; Naber TH
Neth J Med; 2007 Oct; 65(9):339-45. PubMed ID: 17954953
[TBL] [Abstract][Full Text] [Related]
12. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials.
Sandborn WJ; Löfberg R; Feagan BG; Hanauer SB; Campieri M; Greenberg GR
Am J Gastroenterol; 2005 Aug; 100(8):1780-7. PubMed ID: 16086715
[TBL] [Abstract][Full Text] [Related]
13. Oral budesonide in the management of Crohn's disease.
Hofer KN
Ann Pharmacother; 2003 Oct; 37(10):1457-64. PubMed ID: 14519035
[TBL] [Abstract][Full Text] [Related]
14. Oral budesonide for maintenance treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial.
Miehlke S; Madisch A; Bethke B; Morgner A; Kuhlisch E; Henker C; Vogel G; Andersen M; Meier E; Baretton G; Stolte M
Gastroenterology; 2008 Nov; 135(5):1510-6. PubMed ID: 18926826
[TBL] [Abstract][Full Text] [Related]
15. Budesonide is effective in treating lymphocytic colitis: a randomized double-blind placebo-controlled study.
Miehlke S; Madisch A; Karimi D; Wonschik S; Kuhlisch E; Beckmann R; Morgner A; Mueller R; Greinwald R; Seitz G; Baretton G; Stolte M
Gastroenterology; 2009 Jun; 136(7):2092-100. PubMed ID: 19303012
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of controlled-release budesonide in preserving bone mineral density in patients with Crohn's disease.
Abreu MT
Nat Clin Pract Gastroenterol Hepatol; 2005 May; 2(5):210-1. PubMed ID: 16265201
[No Abstract] [Full Text] [Related]
17. Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease.
Thia KT; Sandborn WJ; Lewis JD; Loftus EV; Feagan BG; Steinhart AH; Hanauer SB; Persson T; Sands BE
Am J Gastroenterol; 2008 Dec; 103(12):3123-31. PubMed ID: 18786111
[TBL] [Abstract][Full Text] [Related]
18. Esophagitis in an adolescent patient with Crohn's disease after changing treatment from prednisolone to budesonide.
Weigand K; Wagner-Thiessen E; Stolte M
Z Gastroenterol; 2004 Oct; 42(10):1179-81. PubMed ID: 15508059
[TBL] [Abstract][Full Text] [Related]
19. Replacement of conventional glucocorticoids by oral pH-modified release budesonide in active and inactive Crohn's disease: results of an open, prospective, multicenter trial.
Andus T; Gross V; Caesar I; Schulz HJ; Lochs H; Strohm WD; Gierend M; Weber A; Ewe K; Schölmerich J;
Dig Dis Sci; 2003 Feb; 48(2):373-8. PubMed ID: 12643618
[TBL] [Abstract][Full Text] [Related]
20. Maintenance of Crohn's disease over 12 months: fixed versus flexible dosing regimen using budesonide controlled ileal release capsules.
Green JR; Lobo AJ; Giaffer M; Travis S; Watkins HC;
Aliment Pharmacol Ther; 2001 Sep; 15(9):1331-41. PubMed ID: 11552903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
